Setmelanotide vs Tesamorelin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Setmelanotide

Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).

Full details →

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

Side-by-Side Comparison

Aspect	Setmelanotide	Tesamorelin
Dose Range	1 mg–3 mg	2 mg
Frequency	1x daily	1x daily
Cycle Length	12–52 weeks	8–52 weeks
Route	subcutaneous	subcutaneous
Mechanism	Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes.	Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.
Typical Dosage	Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily.	FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.
Administration	Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing.	Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.
Side Effects	Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s.	Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.
Best For	Fat Loss	Muscle Growth Fat Loss